Abstract 1

GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

B. Slomovitz1,2, V.L. Filiaci3, R.L. Coleman4, J.L. Walker5, A.C. Fleury6, L.L. Holman7 and D.S. Miller8

1 University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA, 2University of Miami Miller School of Medicine, Miami, FL, USA, 3Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, 4The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 5The University of Oklahoma, Oklahoma City, OK, USA, 6Women’s Cancer Center of Nevada, Las Vegas, NV, USA, 7The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 8The University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract 2

Novel intrauterine polymer system delivers everolimus at biologically active levels in rats

J.A. Dottino1, Y. Jiang1, S. Shah2, J. Celestino1, E. Watson3, Q. Zhang1, G. Chisholm1, J. Burks1, A. Mikos1, K.H. Lu1 and M. Yates1

1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Baylor College of Medicine, Houston, TX, USA, 3Rice University, Houston, TX, USA

Abstract 3

Disparities in the allocation of research funding to gynecologic cancers demonstrated by funding to lethality scores

R. Spencer1, L.W. Rice1, C.Y. Ye1 and S. Uppal2

1 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, 2University of Michigan Health Systems, Ann Arbor, MI, USA
Abstract 4
Changes in the Affordable Care Act affecting women: Fiscal 2014-2017

E.J. Pavlik1, M. Geiger2, J.C. Dillon3, C. Sheffer2, T.E. Pavlik2, E.A. Harvey2, B. Wagner2, Q. Yu2, L.A. Baldwin3 and M.S. Johnson4
1 University of Kentucky, Lexington, KY, USA, 2University of Kentucky College of Medicine, Lexington, KY, USA, 3University of Kentucky Medical Center, Lexington, KY, USA

Abstract 5
The Affordable Care Act reduced racial and socioeconomic disparities in access to health insurance among women diagnosed with a gynecologic malignancy

H.A. Moss, L.J. Havrilesky and J. Chino
Duke University Medical Center, Durham, NC, USA

Abstract 6
Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer

K.B. Patel1, A. Pyrzak2, H. Coste1, L.F. Zhang1, R. Sadek1, J.J. Wallbillich1, S. Ghamande2 and B.J. Rungruang1
1 Medical College of Georgia, Augusta, GA, USA, 2Georgia Regents University, Augusta, GA, USA

SCIENTIFIC PLENARY SESSION II: CONTEMPORARY CHALLENGES
ABSTRACTS 7-13
10:30 a.m. – 12:00 p.m.

Abstract 7
Tackling the opioid crisis: Implementation of an ultra-restrictive opioid prescription protocol in patients undergoing major gynecologic surgery radically decreased dispensed opioid without reducing pain control

J.E. Mark1, D. Phoenix1, C.A. Gutierrez2, K. Morrell1, K.H. Eng1, P.C. Mayor1, S.N. Akers1, S.B. Lele1, K. Odunsi1, O. DeLeon1, P.J. Frederick1 and E. Zsiros1
1 Roswell Park Cancer Institute, Buffalo, NY, USA, 2University of Buffalo, Buffalo, NY, USA

Abstract 8
Opioid use in gynecology oncology patients after minimally invasive hysterectomy

E. Weston1, C. Raker2, D. Huang3, A.B. Parker2, K.M. Robison2 and C.A. Mathews2
1 Johns Hopkins School of Medicine, Baltimore, MD, USA, 2Women & Infants Hospital, Brown University, Providence, RI, USA, 3University of California, San Francisco, San Francisco, CA, USA

Abstract 9
Variation of cost and resource utilization associated with the surgical management of women with ovarian cancer

J.A. Rauh-Hain1, A. Melamed2, L.A. Meyer1 and M.G. del Carmen3
1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Massachusetts General Hospital/Harvard University, Boston, MA, USA
Abstract 10
Development of an alternative payment model (APM) for early-stage cervical cancer: Opportunities to reduce cost and improve quality

J.D. Wright, L.J. Havrilesky, R.D. Alvarez, D.E. Cohn, Y. Huang, L.R. Boyd and E.M. Ko
1 Columbia University College of Physicians and Surgeons, New York, NY, USA, 2Duke University Medical Center, Durham, NC, USA, 3University of Alabama at Birmingham, Birmingham, AL, USA, 4The Ohio State University, James Cancer Hospital, Columbus, OH, USA, 5New York University School of Medicine, New York, NY, USA, 6University of Pennsylvania, Philadelphia, PA, USA

Abstract 11
GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients

1Mercy Clinic - Women’s Oncology, Springfield, MO, USA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, 3Memorial Sloan Kettering Cancer Center, New York, NY, USA, 4University of Missouri, Columbia, MO, USA, 5SGNO, Fort Worth, TX, USA, 6Abington Memorial Hospital, Abington, PA, USA, 7University of California, Irvine, Irvine, CA, USA, 8The University of Oklahoma, Oklahoma City, OK, USA, 9Women’s Cancer Center of Nevada, Las Vegas, NV, USA, 10Cox Health, Springfield, MO, USA, 11University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 12Women & Infants Hospital, Brown University, Providence, RI, USA, 13Lewis Cancer & Research Pavilion @ St. Joseph’s Candler, Savannah, GA, USA, 14The University of Arizona Cancer Center, Tucson, AZ, USA

Abstract 12
The FILM Trial: A randomized phase III multicenter study assessing near infrared fluorescence in the identification of sentinel lymph nodes (SLN)

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Laval University, L’Hotel-Dieu de Quebec, Quebec City, QC, Canada, 3Duke University Medical Center, Durham, NC, USA, 4Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5Bay Area Gynecology Oncology, San Jose, CA, USA, 6Instituto Gyneco-Oncologico, Caguas, PR, USA, 7Sunnybrook Odette Cancer Center, Toronto, ON, Canada

Abstract 13
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?

1The Ohio State University, James Cancer Hospital, Columbus, OH, USA, 2The Ohio State University, Columbus, OH, USA, 3L’Hotel-Dieu de Quebec, Quebec City, QC, Canada, 4Laval University, L’Hotel-Dieu de Quebec, Quebec City, QC, Canada, 5University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 6Johns Hopkins Hospital, Baltimore, MD, USA, 7The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 8Florida Hospital Cancer Institute, Orlando, FL, USA, 9Memorial Sloan Kettering Cancer Center, New York, NY, USA
Abstract 14

An in vitro evaluation of neoantigens derived from gene fusion events in ovarian cancer patients

1Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, 2University of Pittsburgh/Magee-Womens Hospital, Pittsburgh, PA, USA, 3University of Pittsburgh, Pittsburgh, PA, USA, 4Magee-Womens Research Institute, Pittsburgh, PA, USA

Abstract 15

Adverse events and responses in patients with recurrent ovarian cancer undergoing early-phase immune checkpoint inhibitor clinical trials

E.M. Hinchcliff, D. Hong, H. Le, G. Chisholm, R. Iyer, A. Naing and A.A. Jazaeri
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract 16

A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer

A.Y. Liu1, J.G. Cohen1, C. Walsh2, C.H. Holschneider3 and A.K. Sinno1
1University of California, Los Angeles, Los Angeles, CA, USA, 2Cedars-Sinai Medical Center, Los Angeles, CA, USA, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Sunday, March 25, 2018

Abstract 17

Utilizing the patient-reported outcomes measurement information system (PROMIS) to improve referral to ancillary support services for severely symptomatic patients with gynecologic cancer

G.M. Gressel1, S.M. Dioun1, M. Richley1, A.R. Van Arsdale2, S. Isani3, N.S. Nevadunsky2, D. Smotkin2, H.O. Smith2, D.Y.S. Kuo2 and A.P. Novetsky2
1Montefiore Medical Center, Bronx, NY, USA, 2Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA, 3Albert Einstein College of Medicine, New York, NY, USA
Abstract 18
PARP 7 has a significant role in overall survival of patients with ovarian cancer

L.H. Palavalli Parsons and J.S. Lea
The University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract 19
Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC)

J.R. Foote¹, A. Alvarez-Secord¹, M.I. Liang², J.A. Ehrisman¹, D.E. Cohn³, E. Jewell⁴ and L.J. Havrilesky¹
¹Duke University Medical Center, Durham, NC, USA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, ³The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract 20
Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial

R. Lord¹, M.R. Mirza², L. Woelber³, A. Lesoin⁴, M.J. Pineda⁵, U. Peen⁶, S.J. Hazard⁷ and U.A. Matulonis⁸
¹National Cancer Research Institute (NCRI) and Clatterbridge Cancer Center, Wirral, United Kingdom, ²The Nordic Society of Gynecological Oncology (NSGO) and Righospitalet-Copenhagen University Hospital, Copenhagen, Denmark, ³Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and University Medical Center Hamburg - Eppendorf, Hamburg, Germany, ⁴Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) and Centre Oscar Lambret Department de Cancérologie Sénologique, Lille, France, ⁵Ironwood Cancer and Research Center, Mesa, AZ, USA, ⁶NSGO and Herlev Hospital, Herlev, Denmark, ⁷Tesaro, Inc., Waltham, MA, USA, ⁸Dana-Farber Cancer Institute, Boston, MA, USA

Abstract 21
Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer?

J.A. Dottino¹, H.A. Moss², K.H. Lu¹, A.A. Secord³ and L.J. Havrilesky²
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Duke University Medical Center, Durham, NC, USA, ³Duke Cancer Institute, Durham, NC, USA

Abstract 22
Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002)

A.D. Santin¹ and A.N. Fader²
¹Yale University School of Medicine, New Haven, CT, USA, ²Johns Hopkins School of Medicine, Baltimore, MD, USA
Abstract 23 Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P


1NYU Langone Health, New York, NY, USA, 2Massachusetts General Hospital Cancer Center, Boston, MA, USA, 3Mercy Clinic - Women’s Oncology, Springfield, MO, USA, 4Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, 5Washington University School of Medicine in St. Louis, St. Louis, MO, USA, 6Duke Cancer Institute, Durham, NC, USA, 7University of California Irvine Medical Center, Orange, CA, USA, 8University of Iowa Hospitals and Clinics, Iowa City, IA, USA, 9The Ohio State University, James Cancer Hospital, Columbus, OH, USA, 10Women & Infants Hospital, Brown University, Providence, RI, USA, 11The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 12Rush University Medical Center, Chicago, IL, USA, 13Memorial Sloan Kettering Cancer Center, New York, NY, USA, 14Weill Cornell Medical College, New York, NY, USA

Abstract 24 IAP antagonism enhances anti-tumor activity of docetaxel or panobinostat in ovarian cancer cell lines


1Walter Reed National Military Medical Center, Bethesda, MD, USA, 2National Institutes of Health, Bethesda, MD, USA, 3National Cancer Institute, Bethesda, MD, USA, 4Astex Pharmaceuticals, Cambridge, United Kingdom

Abstract 25 Development of a high-affinity anti-galectin-3 antibody targeting interactions between MUC16/CA-125 and galectin-3 to inhibit oncogenic properties in serous ovarian cancer

M. Stasenko, T.D. Rao, F. Weis-Garcia and D. Spriggs

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract 26 Targeting the TIE2 pathway with a novel small molecule vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitor in high-grade serous ovarian cancer

L.P. Cobb1, A. Rickard2, J. Herbert2, G. Hanna2, G. Palmer2, S. Siamakpour-Reihani2, Z. Huang2, K. Peters2, C. Kontos2, A. Berchuck4 and A.A. Secord5

1Duke University School of Medicine, Durham, NC, USA, 2Duke University, Durham, NC, USA, 3Aerpio Therapeutics, Cincinnati, OH, USA, 4Duke University Medical Center, Durham, NC, USA, 5Duke Cancer Institute, Durham, NC, USA

EDUCATION FORUM V: PALLIATIVE CARE ABSTRACT 27
3:30 p.m. – 5:00 p.m.

Abstract 27 Trends in place of death among gynecologic cancer patients in the United States

K. Hicks-Courant1, A. Melamed2 and J.A.A. Rauh-Hain2

1Tufts Medical Center, Boston, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA
SUNRISE SEMINAR V: HEALTH CARE ECONOMICS
ABSTRACT 28
6:30 a.m. – 7:30 a.m.

Abstract 28
Indicated presurgical testing is a priority to achieve high-quality, cost-effective oncologic health care delivery

Memorial Sloan Kettering Cancer Center, New York, NY, USA

FOCUSED PLENARY I: PRECLINICAL AND TRANSLATIONAL MEDICINE
ABSTRACTS 29-32
9:15 a.m. – 10:15 a.m.

Abstract 29
Simvastatin has anti-tumorigenic effects in endometrial cancer via reversal of obesity-driven upregulation of lipid biosynthesis

L. West¹, L.H. Clark¹, S.R. Pierce¹, Y. Yin¹, Z. Fang¹, D. Lee², C. Zhou¹ and V.L. Bae-Jump¹
¹University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Omic Insight, LCC, Durham, NC, USA

Abstract 30
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-a

D. Torres, X. Hou, L.K. Bale, E.P. Heinzen, M.J. Maurer, Q. Zhang, C.A. Conover and S.J. Weroha
Mayo Clinic, Rochester, MN, USA

Abstract 31
Expression of dopamine receptor D2 in endometrial tumors and the impact of DRD2 blockade on cancer proliferation

S.R. Pierce¹, M. Asher¹, Z. Fang¹, L. West¹, Y. Yin¹, V. Prabhu², C. Xu¹, C. Zhou¹ and V.L. Bae-Jump¹
¹University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²Oncoceutics, Philadelphia, PA, USA

Abstract 32
Stromal cell expression of the receptor tyrosine kinase DDR2 promotes ovarian cancer metastasis

Washington University School of Medicine in St. Louis, St. Louis, MO, USA
FOCUSED PLENARY II: REDUCING COST AND PAIN
ABSTRACTS 33-37
9:15 a.m. – 10:15 a.m.

Abstract 33
Can the ASCO alternative payment model achieve cost savings in ovarian cancer care?

H.A. Moss¹, M. Dinan², M.V. Georgieva², L.H. Hendrix² and L.J. Havrilesky¹
¹Duke University Medical Center, Durham, NC, USA, ²Duke Cancer Institute, Durham, NC, USA

Abstract 34
Evaluation of financial toxicity in women with gynecologic malignancies: A cross-sectional study

E.M. Webster¹, S. Chatterjee², L. Gabor¹, R.M. Vattakalam¹, J.Y. Hou¹, A.I. Tergas¹ and J.D. Wright³
¹NYP/Columbia University Medical Center, New York, NY, USA, ²NYPH, Columbia University Medical Center and Weill Cornell Medical College, New York, NY, USA, ³Columbia University College of Physicians and Surgeons, New York, NY, USA

Abstract 35
Use of lay navigation in gynecologic oncology patients: A model to reduce costs

R.P. Rocconi¹, P. Sharma², A. Azuero³, J.M. Scalici¹, J. Young Pierce¹, N.L. Jones¹, K.S. Bevis², E.E. Partridge², E. Kvale², G.B. Rocque² and M. Pisu²
¹Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ²University of Alabama at Birmingham, Birmingham, AL, USA

Abstract 36
A comparison of liposomal bupivacaine to bupivacaine HCl in tranversus abdominis planus block for abdominal gynecologic surgery: A randomized controlled trial

H. Ching¹, R.F. Atkins¹, E.R. Burton², M.I. Edelson², J.I. Sorosky² and M.S. Shahin²
¹Abington Memorial Hospital, Abington, PA, USA, ²Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, USA

Abstract 37
Impact of enhanced recovery after surgery (ERAS) protocol on postoperative pain control in chronic narcotic users


FOCUSED PLENARY III: NEW INSIGHTS INTO RARE TUMORS
ABSTRACTS 38-42
9:15 a.m. – 10:15 a.m.

Abstract 38
KMT2D/MLL2 loss of function is a novel driver of disease recurrence in adult-type granulosa cell tumors of the ovary

R.T. Hillman, J. Celestino, K.H. Lu, D.M. Gershenson, R. Broaddus and P.A. Futreal The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract 39
Integrated genomic analyses distinguish leiomyosarcomas arising at distinct anatomic origins

M.L. Anderson¹ and A.J. Lazar²
¹Baylor College of Medicine, Houston, TX, USA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Abstract 40

Single-course methotrexate and single-course combined methotrexate–dactinomycin: A phase III randomized controlled clinical trial in treatment of low-risk gestational trophoblastic neoplasm

L. Chen¹, R. Yin², L. Xi³, J. Jiang⁴, X. Li⁵, P. Qu⁶, B. Kong⁷, D. Ma⁸, X. Xie¹ and W. Lv¹
¹Women’s Hospital, School of Medicine, Zhejiang University, Zhejiang, China, ²West China Second University Hospital, Sichuan, China, ³Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ⁴Qilu Hospital of Shandong University, Jinan, China, ⁵Shengjing Hospital of China Medical University, Shenyang, China, ⁶Tianjin Central Hospital of Gynecology Obstetrics, Nankai University, Tianjin, China, ⁷Tongji Hospital of Tongji Medical College, Wuhan, China

Abstract 41

The impact of uterine re-curettage on the number of chemotherapy courses in treatment of post molar gestational trophoblastic neoplasia: A randomized controlled study

R. Hemida¹, B.E. Deek¹, M. Arafa¹, E. Toson¹, E.L. Vos², C.W. Burger² and H.C.V. Doorn²
¹Mansoura University, Mansoura, Egypt, ²Erasmus University Medical Centre, Rotterdam, Netherlands

Abstract 42

Molecular profiling of ovarian germ cell tumors

M. Stasenko¹, A. Zehir¹, A. Snyder¹, D. Reales¹, D. DeLair¹, R.A. Soslow¹, N.R. Abu-Rustum¹, C.A. Aghajanian¹, D. Feldman¹ and D.B. Solit¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA, ²Weill Cornell Medical College, New York, NY, USA

Abstract 43

Moving beyond “complete surgical resection” and “optimal”: Is low-volume residual disease another option?

B.L. Manning-Geist¹,² K. Hicks-Courant³, A.A. Gockley⁴, R.M. Clark⁵, M.G. del Carmen⁵, J.O. Schorge², N.S. Horowitz², R.S. Berkowitz⁶, M.G. Muto⁷ and M.J. Worley Jr.⁸
¹Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA, ²Massachusetts General Hospital, Boston, MA, USA, ³Tufts Medical Center, Boston, MA, USA, ⁴Harvard Medical School, Boston, MA, USA, ⁵Massachusetts General Hospital/Harvard University, Boston, MA, USA, ⁶Brigham and Women’s Hospital, Boston, MA, USA, ⁷Dana-Farber Cancer Institute, Boston, MA, USA, ⁸Brigham and Women’s Hospital/Harvard University, Boston, MA, USA

Abstract 44

Career demands of gynecologic oncology have a substantial impact on family planning

M. Song¹, A. Kapoor¹, R. Isaksson Vogel², M.A. Geller² and D.G.K. Teoh³
¹University of Minnesota Cancer Center, Minneapolis, MN, USA, ²University of Minnesota, Minneapolis, MN, USA

Abstract 45

The career effects of parenting on female and male gynecologic oncologists

L.B. Beffa¹, A.R. Stuckey¹, E.K. Hill², A.K. Brown³, M.E. Gordinier⁴, C. Raker⁵, M. Clark⁶ and K.M. Robison¹
¹Women & Infants Hospital, Brown University, Providence, RI, USA, ²University of Iowa, Iowa City, IA, USA, ³Hartford Hospital, Hartford, CT, USA, ⁴Norton Healthcare, Louisville, KY, USA, ⁵University of Massachusetts Medical Center, Worcester, MA, USA
Abstract 46

Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis

University of Alabama at Birmingham, Birmingham, AL, USA

Abstract 47

Predictors of early treatment discontinuation in ovarian cancer patients on checkpoint blockade immunotherapy

1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Weill Cornell Medical College, New York, NY, USA

Abstract 48

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

1Dana-Farber Cancer Institute, Boston, MA, USA, 2Massachusetts General Hospital/Harvard University, Boston, MA, USA, 3Long Island Jewish Medical Center, New Hyde Park, NY, USA, 4Brigham and Women’s Hospital, Boston, MA, USA, 5Lifespan Cancer Institute, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA, 6Harvard Medical School, Boston, MA, USA, 7Massachusetts General Hospital, Boston, MA, USA

Abstract 49

Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer

1Dana-Farber Cancer Institute, Boston, MA, USA, 2Massachusetts General Hospital/Harvard University, Boston, MA, USA, 3Beth Israel Deaconess Medical Center, Boston, MA, USA, 4Massachusetts General Hospital/Harvard University, Boston, MA, USA, 5University of Alabama at Birmingham, Birmingham, AL, USA, 6Harvard Medical School, Boston, MA, USA, 7Lifespan Cancer Institute, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA, 8University of Chicago Medical Center, Chicago, IL, USA

Abstract 50

Gene set enrichment clustering and the tumor microenvironment in primary high-grade serous ovarian cancer (HGSOC)

1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2University of Cambridge, Cambridge, United Kingdom, 3Adaptive Biotechnologies, Seattle, WA, USA
Abstract 51

GOG 244, The lymphedema and gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lower extremity lymphedema


1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, 3University of Missouri, Columbia, MO, USA, 4Mercy Clinic - Women’s Oncology, Springfield, MO, USA, 5SGNO, Fort Worth, TX, USA, 6Abington Memorial Hospital, Abington, PA, USA, 7University of California, Irvine, Irvine, CA, USA, 8The University of Oklahoma, Oklahoma City, OK, USA, 9Women’s Cancer Center of Nevada, Las Vegas, NV, USA, 10University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 11Women & Infants Hospital, Brown University, Providence, RI, USA, 12Lewis Cancer & Research Pavilion @ St. Joseph’s Candler, Savannah, GA, USA, 13The University of Arizona Cancer Center, Tucson, AZ, USA

Abstract 52

Patient-reported symptom burden and functional recovery before and after enhanced recovery after surgery (ERAS) implementation: A comparison between open and minimally invasive surgery

L.A. Meyer1, Q. Shi1, J.D. Lasala1, A.M. Nick2, M.D. Iniesta1, A.M. Siverand1, C. Corzo1, X.S. Wang1, K.H. Lu1 and P.T. Ramirez1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2St. Thomas Medical Partners, University of Tennessee Health Sciences Center, Nashville, TN, USA

Abstract 53

Gestational trophoblastic disease electronic consults: What do patients and physicians want to know?

R. Nitecki1, N.S. Horowitz2, K.M. Elias2, D.P. Goldstein3 and R.S. Berkowitz2

1Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA, 2Brigham and Women’s Hospital, Boston, MA, USA, 3Brigham and Women’s Hospital/Harvard University, Boston, MA, USA

Abstract 54

It’s like "magic": The mobile application for genetic information on cancer


University of Minnesota, Minneapolis, MN, USA

Abstract 55

Rethinking cervical cancer screening guidelines in an aging U.S. population

S.E. Dilley, J.A. O’Donnell, H.J. Smith, S. Bae and W. Huh

University of Alabama at Birmingham, Birmingham, AL, USA

Abstract 56

Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower extremity lymphedema after sentinel lymph node mapping (SLNM) compared to lymphadenectomy

M.M. Leitao Jr.1, N.R. Gómez-Hidalgo2, A. Iasonos1, Q. Zhou1, M. Mezzancello1, K. Chang1, J. Ward1, R.R. Barakat1, D.S. Chi1, K. Long Roche1, Y. Sonoda1, C.L. Brown1, J.J. Mueller1, G.J. Gardner1, E. Jewell1, V. Broach1, O. Zivanovic1, S.C. Dowdy3, A. Mariani1 and N.R. Abu-Rustum1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2NYC/Barnes-Jewish Hospital, St. Louis, MO, USA, 3Mayo Clinic, Rochester, MN, USA
Abstract 57  
A novel site-specific proteomic screening test for ovarian cancer in a large prospective multi-institutional clinical study

Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Abstract 58  
Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers

¹Moffitt Cancer Center-University of South Florida, Tampa, FL, USA, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ³New York University School of Medicine, New York, NY, USA, ⁴University of Iowa Carver College of Medicine, Iowa City, IA, USA, ⁵Weill Cornell Medical College, New York, NY, USA, ⁶University of Iowa Hospitals and Clinics, Iowa City, IA, USA, ⁷The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ⁸Washington University School of Medicine in St. Louis, St. Louis, MO, USA, ⁹Duke Cancer Institute, Durham, NC, USA, ¹⁰University of California Irvine Medical Center, Orange, CA, USA, ¹¹Women & Infants Hospital, Brown University, Providence, RI, USA, ¹²The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ¹³Rush University Medical Center, Chicago, IL, USA

Abstract 59  
Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002)

D. Weng¹, H. Wang¹, C. Zhu¹, B. Cui³, C. Wang¹, K. Li¹, Q. Gao¹, X. Cheng¹, X. Yang¹, J. Jiang¹, Y. Zhang¹, B. Kong³, X. Xie² and D. Ma¹
¹Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Women's Hospital, School of Medicine, Zhejiang University, Zhejiang, China, ³Qilu Hospital, Shandong University, Jinan, China

Abstract 60  
Come back in six months, or never? Defining surveillance and survivorship in gynecologic malignancies with an evidence-based approach

The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Abstract 61  Benign surgery performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality?

E.L. Barber¹, A.L. Alexander¹, S. Shahabi² and E.C. Rossi³
¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, ²Western CT Health Network/Danbury Hospital, Danbury, CT, USA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


University of Alabama at Birmingham, Birmingham, AL, USA

Abstract 63  The utility of preoperative PET/CT in the detection of extrauterine disease in high-risk endometrial cancer: A prospective study

K.I. Stewart¹, B. Chasen¹, W.D. Erwin¹, N.D. Fleming¹, S.N. Westin¹, M. Frumovitz¹, P.T. Ramirez¹, S.M. Dioun², K.H. Lu¹, F. Wong¹ and P.T. Soliman¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Montefiore Medical Center, Bronx, NY, USA

Abstract 64  A comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors

P.C. Mayor¹, L. Gay², K. Fan³, P.J. Frederick¹, R.N. Eskander¹, J. Sun², J.S. Ross⁵, R. Kurzrock⁶, S.N. Akers¹, S.B. Lele¹, K. Odunsi¹, E. Zsiros¹ and J.A. Elvin²
¹Roswell Park Cancer Institute, Buffalo, NY, USA, ²Foundation Medicine, Inc., Cambridge, MA, USA, ³University of Buffalo, Buffalo, NY, USA, ⁴UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, ⁵Albany Medical College, Albany, NY, USA, ⁶University of California San Diego, La Jolla, CA, USA

Abstract 65  Development and validation of a risk calculator for adverse perioperative outcomes for women with ovarian cancer

S. Cham, A.I. Tergas, J.Y. Hou, C. St. Clair, C. V. Ananth, D.L. Hershman and J.D. Wright
NYP/Columbia University Medical Center, New York, NY, USA

Abstract 66  Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer

L. Ge¹, N. Li² and L.Y. Wu²
¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Abstract 67

A subgroup of cases with a high immunogenic profile in homologous recombination-proficient high-grade serous ovarian carcinoma: Possible candidates for checkpoint blockade therapy

1Saitama Medical University International Medical Center, Hidaka, Japan, 2The University of Tokyo Hospital, Tokyo, Japan, 3Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan

Abstract 68

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer: Preliminary results of a phase II randomized clinical trial

T.P. Diaz-Montes, F. El-Sharkawy, V. Gushchin, H.S. Ryu, M. Sritig and A. Sardi
Mercy Medical Center, Baltimore, MD, USA

Abstract 69

Utilization of preoperative PET-CT and pelvic MRI reduces multimodality therapy in the care of women with early-stage cervical carcinoma

E.J. Diver1, E.M. Hinchcliff2, A.A. Gockley2, A. Melamed1, L. Contrino1, S. Feldman1 and W.B. Growdon2
1Massachusetts General Hospital, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA, 3Brigham and Women’s Hospital, Boston, MA, USA

Abstract 70

Identification of ovarian cancer patients for immunotherapy by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA)

J. Feinberg1, J.A. Elvin2, S. Bellone1 and A.D. Santin1
1Yale University School of Medicine, New Haven, CT, USA, 2Foundation Medicine, Inc., Cambridge, MA, USA

Abstract 71

Evaluation of circulating tumor DNA in patients with endometrial cancer harboring somatic PIK3CA or KRAS mutations: A potential high-risk factor for recurrence

D. Shintani1, T. Hihara2, A. Ogasawara3, A. Yabuno3, K. Fujiwara1, K. Tai2 and K. Hasegawa1
1Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Japan, 2Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba, Japan, 3Saitama Medical University International Medical Center, Hidaka, Japan

Abstract 72

Tackling the opioid crisis: Reduced postoperative oral and intravenous opioid use after implementation of an enhanced recovery after surgery (ERAS) program in gynecologic oncology patients

H.J. Gray1, C. Rind1, E.S. Wu1, B.A. Goff2, H.K. Tamimi1, K. Pennington2 and R.R. Urban1
1University of Washington Medical Center, Seattle, WA, USA, 2University of Washington School of Medicine, Seattle, WA, USA
Abstract 73  
GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study

T.C. Longoria¹, M. Sill², B.J. Monk³, J. Fruehauf¹, S.Y. Liao¹, R. Emerson⁴, J.H. Kim¹, R.S. Mannel⁷, Y.C. Lee⁶, C.A. Mathews⁸, L.M. Randall¹, K.M. Darcy¹⁰, M.J. Birrer¹¹ and K.S. Tewari¹
¹University of California Irvine Medical Center, Orange, CA, USA, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ³University of Arizona Cancer Center, Phoenix, AZ, USA, ⁴University of California, Irvine, CA, USA, ⁵St. Joseph’s Hospital and Medical Center, Urbana, IL, USA, ⁶Indiana University School of Medicine, Indianapolis, IN, USA, ⁷The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ⁸SUNY Downstate, Brooklyn, NY, USA, ⁹Women & Infants Hospital, Brown University, Providence, RI, USA, ¹⁰Gynecologic Cancer Center of Excellence, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Annandale, VA, USA, ¹¹Massachusetts General Hospital/Harvard University, Boston, MA, USA

Abstract 74  
Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

U.A. Matulonis¹, K.N. Moore², L.P. Martin³, I.B. Vergote⁴, C.M. Castro⁵, L. Gilbert⁶, A. Berkenblit⁷, M.J. Birrer⁸ and D.M. O’Malley⁹
¹Dana-Farber Cancer Institute, Boston, MA, USA, ²The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ³Fox Chase Cancer Center, Philadelphia, PA, USA, ⁴University Hospital Leuven, Leuven, Belgium, ⁵Massachusetts General Hospital, Boston, MA, USA, ⁶McGill University Health Centre, Montreal, QC, Canada, ⁷ImmuGen, Inc., Waltham, MA, USA, ⁸Massachusetts General Hospital/Harvard University, Boston, MA, USA, ⁹The Ohio State University, James Cancer Hospital, Columbus, OH, USA

Abstract 75  
Concordance of germline multigene panel testing with prior microsatellite instability and immunohistochemistry analyses in endometrial cancer patients

K. Jasperson¹, C.R. Espenschied¹, H. Hampel², P. Reineke¹, T. Pesaran¹, V. Speare¹, J. Profato¹ and I.M. Frayling³
¹Ambry Genetics, Aliso Viejo, CA, USA, ²The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, ³Cardiff University, Cardiff, United Kingdom

Abstract 76  
Sentinel lymph node mapping (SLNM) in endometrioid endometrial cancer: Does it work in the real world?

O. Valieva¹, D.M. Greer², J.F. Kram¹, E. Schmit², E.L. Dickson¹ and S.A. Kamelle²
¹Aurora Health Care, Gurnee, IL, USA, ²Aurora Health Care, Milwaukee, WI, USA

Abstract 77  
Germline BRCA mutation rate in Southern California Latina women

L.J. Hong¹, R. Gonzalez², S. Abu-Tabikh², L. Cristiano², J. Unternaehrer-Hamm¹ and Y.J.M. Ioffe¹
¹Loma Linda University School of Medicine, Loma Linda, CA, USA, ²Loma Linda University Medical Center, Loma Linda, CA, USA

Abstract 78  
Phase I trial of Vigil® personalized engineered autologous tumor cells (EATC) in ovarian cancer

R.P. Rocconi¹, J.M. Scalici¹, M. Barve², L. Manning³, G. Wallraven³, N. Senzer³ and J. Nemunaitis³
¹Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ²Texas Oncology, P.A., Dallas, TX, USA, ³Gradalis, Inc., Dallas, TX, USA
Abstract 78  A prospective, randomized control trial evaluating the impact of backfill versus spontaneous voiding trial on discharge time for gynecologic oncology patients undergoing laparoscopic hysterectomy

1Brigham and Women’s Hospital/Harvard University, Boston, MA, USA, 2Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA, 3Emory University, Atlanta, GA, USA, 4Brigham and Women’s Hospital, Boston, MA, USA

Abstract 79  Adoptive dendritic cell transfer following platinum-based chemotherapy extends overall host survival in a preclinical model of metastatic ovarian cancer

A. Buskwofie1, E. Teran-Cabanillas2, T. Sandoval Medina2 and J.R. Cubillos-Ruiz2
1NYPH, Columbia University Medical Center and Weill Cornell Medical College, New York, NY, USA, 2Weill Cornell Medical College, New York, NY, USA

Abstract 80  Zoptec: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155)

1The University of Texas Southwestern Medical Center, Dallas, TX, USA, 2GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 3H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, 4Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 5University Hospital Leuven, Leuven, Belgium, 6Academic Medical Centre, Amsterdam, Netherlands, 7Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, 8Imperial College Healthcare NHS Trust, London, United Kingdom

Abstract 81  Vaginal brachytherapy is associated with improved overall survival in stage IB endometrioid endometrial carcinoma: A propensity matched, National Cancer Data Base study

M.M. AlHilli1, S. Amarnath1 and S.C. Dowdy2
1The Cleveland Clinic Foundation, Cleveland, OH, USA, 2Mayo Clinic, Rochester, MN, USA

Abstract 82  Favorable tumor immunophenotype is associated with homologous recombination deficiency in ovarian carcinoma

C.B. Morse1, M.N. Toukatly1, M.I. Harrell2, K.J. Agnew3, S.S. Bernards3, B.M. Norquist2, K. Pennington1, M.R. Kilgore1, R.L. Garcia1 and E.M. Swisher1
1University of Washington Medical Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3University of Washington School of Medicine, Seattle, WA, USA

Abstract 83  Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian

A. Sackeyfio1, F. Nussey2, M. Friedlander3 and E. Pujade-Lauraine4
1AstraZeneca, Cambridge, United Kingdom, 2Western General Hospital, Edinburgh, United Kingdom, 3Prince of Wales Hospital, Randwick, Australia, 4Hôpital Hotel Dieu, Paris, France
Abstract 84  
Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer

N.L. Jones¹, J. Xiu², T. Herzog³ and I. Winer⁴
¹Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ²Caris Life Sciences, Irving, TX, USA, ³UC Health Barrett Cancer Center, Cincinnati, OH, USA, ⁴Wayne State University, Detroit, MI, USA

Abstract 85  
Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy

I. Winer¹, N.L. Jones², J. Xiu³, A. Ellerbrock³, J. Brown⁴ and T. Herzog⁵
¹Wayne State University, Detroit, MI, USA, ²Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ³Caris Life Sciences, Irving, TX, USA, ⁴Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, ⁵UC Health Barrett Cancer Center, Cincinnati, OH, USA

Abstract 86  
Improving the efficacy of PARP inhibition with a novel ATR inhibitor, ATRN119, in ovarian high-grade serous cancers

E. George¹, H. Kim², L.R. Butler³, M.A. Morgan², O. Gilad³, E.J. Brown¹ and F. Simpkins²
¹Hospital of the University of Pennsylvania, Philadelphia, PA, USA, ²University of Pennsylvania, Philadelphia, PA, USA, ³Atrin Pharmaceuticals, Doylestown, PA, USA

Abstract 87  
System-wide implementation of a perioperative practice-changing bundle to lower surgical site infections in gynecologic oncology: Outcome effect and impact of variations in compliance

University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Abstract 88  
CA-125 is a useful predictor of disease status in uterine carcinosarcoma

M.S. Ross¹, C.K. Chandler¹, E. Elishaev1, N. Siripong², J. Berger¹, J.L. Kelley III¹ and S.E. Taylor¹
¹Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, ²University of Pittsburgh/Magee-Womens Hospital, Pittsburgh, PA, USA